Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 7/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.35 |
| ▸ | COMT | P21964 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | ACSS2 | Q9NR19 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4067400 | 1.00 | NFE2L2 (0.35) | NFE2L2PIK3CACOMTMEN1POLB | |
| SCHEMBL4067398 | 1.00 | NFE2L2 (0.35) | NFE2L2PIK3CACOMTMEN1POLB | |
| SCHEMBL4074964 | 0.93 | NFE2L2 (0.34) | NFE2L2PIK3CACOMTMEN1POLB | |
| SCHEMBL4068413 | 0.81 | NFE2L2 (0.45) | NFE2L2PIK3CACOMTKDM4E | |
| SCHEMBL4078039 | 0.76 | PTGDR2 (0.37) | NFE2L2PIK3CACOMTMEN1KMT2A | |
| SCHEMBL4067334 | 0.73 | KDM4E (0.36) | NFE2L2PIK3CACOMTMEN1POLB | |
| SCHEMBL4067339 | 0.73 | KDM4E (0.36) | NFE2L2PIK3CACOMTMEN1POLB | |
| SCHEMBL4073466 | 0.72 | HTR2A (0.44) | NFE2L2PIK3CACOMTPOLBKDM4E | |
| SCHEMBL4484230 | 0.72 | HTR2A (0.44) | NFE2L2PIK3CACOMTPOLBKDM4E | |
| SCHEMBL4071902 | 0.72 | HTR2A (0.44) | NFE2L2PIK3CACOMTPOLBKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7592456-B2 | Arylsulfonylnaphthalene derivatives as 5HT2A antagonists | MERCK SHARP & DOHME LIMITED (GB) | 2009-09-22 | — | — | US | disclosed |
| EP-1824817-B1 | ARYLSULFONYLNAPHTHALENE DERIVATIVES AS 5HT2A ANTAGONISTS | MERCK SHARP & DOHME (GB) | 2009-02-04 | — | — | EP | disclosed |
| US-20070281952-A1 | Arylsulfonylnaphthalene Derivatives As 5Ht2a Antagonists | MERCK SHARPE & DOHME LIMITED (GB) | 2007-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070281952-A1 | Arylsulfonylnaphthalene Derivatives As 5Ht2a Antagonists | HTR2A, HTR2C, HTR1A | NFE2L2 2686/4885PIK3CA 4160/4885COMT 493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.